Literatura académica sobre el tema "Mesothelioma, immune-checkpoint inhibitors, tumor mutational burden"
Crea una cita precisa en los estilos APA, MLA, Chicago, Harvard y otros
Consulte las listas temáticas de artículos, libros, tesis, actas de conferencias y otras fuentes académicas sobre el tema "Mesothelioma, immune-checkpoint inhibitors, tumor mutational burden".
Junto a cada fuente en la lista de referencias hay un botón "Agregar a la bibliografía". Pulsa este botón, y generaremos automáticamente la referencia bibliográfica para la obra elegida en el estilo de cita que necesites: APA, MLA, Harvard, Vancouver, Chicago, etc.
También puede descargar el texto completo de la publicación académica en formato pdf y leer en línea su resumen siempre que esté disponible en los metadatos.
Artículos de revistas sobre el tema "Mesothelioma, immune-checkpoint inhibitors, tumor mutational burden"
Minchom, Anna, Wei Yuan, Mateus Crespo, Bora Gurel, Ines Figueiredo, Andrew Wotherspoon, Susana Miranda et al. "Molecular and immunological features of a prolonged exceptional responder with malignant pleural mesothelioma treated initially and rechallenged with pembrolizumab". Journal for ImmunoTherapy of Cancer 8, n.º 1 (marzo de 2020): e000713. http://dx.doi.org/10.1136/jitc-2020-000713.
Texto completoMahadevan, Daruka, Li Ma, Kai Treuner, Jenna Wong y Catherine Schnabel. "330 Integration of molecular cancer classification and next-generation sequencing to identify metastatic patients eligible for immune checkpoint inhibitors". Journal for ImmunoTherapy of Cancer 9, Suppl 2 (noviembre de 2021): A356. http://dx.doi.org/10.1136/jitc-2021-sitc2021.330.
Texto completoSokol, Ethan, Natalie Danziger, Dean Pavlick, Julia Andrea Elvin, Jo-Anne Vergilio, Jonathan Keith Killian, Douglas I. Lin et al. "Clinically aggressive malignancies associated with STK11 germline mutations (STK11GCa): A comprehensive genomic profiling (CGP) study." Journal of Clinical Oncology 38, n.º 15_suppl (20 de mayo de 2020): 3558. http://dx.doi.org/10.1200/jco.2020.38.15_suppl.3558.
Texto completoLujambio, Amaia. "The more (mutations), the better". Science Translational Medicine 11, n.º 477 (30 de enero de 2019): eaaw5320. http://dx.doi.org/10.1126/scitranslmed.aaw5320.
Texto completoHsiehchen, David, Magdalena Espinoza, Cristina Valero, Chul Ahn y Luc G. T. Morris. "Impact of tumor mutational burden on checkpoint inhibitor drug eligibility and outcomes across racial groups". Journal for ImmunoTherapy of Cancer 9, n.º 11 (noviembre de 2021): e003683. http://dx.doi.org/10.1136/jitc-2021-003683.
Texto completoAn, Ho Jung, Hong Jae Chon y Chan Kim. "Peripheral Blood-Based Biomarkers for Immune Checkpoint Inhibitors". International Journal of Molecular Sciences 22, n.º 17 (30 de agosto de 2021): 9414. http://dx.doi.org/10.3390/ijms22179414.
Texto completoGiordano, Frank A., Marlon R. Veldwijk, Carsten Herskind y Frederik Wenz. "Radiotherapy, tumor mutational burden, and immune checkpoint inhibitors: time to do the math". Strahlentherapie und Onkologie 194, n.º 10 (20 de julio de 2018): 873–75. http://dx.doi.org/10.1007/s00066-018-1341-z.
Texto completoDuchemann, Boris, Jordi Remon, Marie Naigeon, Laura Mezquita, Roberto Ferrara, Lydie Cassard, Jean Mehdi Jouniaux et al. "Integrating Circulating Biomarkers in the Immune Checkpoint Inhibitor Treatment in Lung Cancer". Cancers 12, n.º 12 (3 de diciembre de 2020): 3625. http://dx.doi.org/10.3390/cancers12123625.
Texto completoAcosta-Medina, Aldo A., Jithma P. Abeykoon, Surendra Dasari, Antonious Z. Hazim, N. Nora Bennani, Terra Lasho, Aishwarya Ravindran et al. "Tumor Mutational Burden in Histiocytic Neoplasms". Blood 138, Supplement 1 (5 de noviembre de 2021): 3634. http://dx.doi.org/10.1182/blood-2021-153128.
Texto completoBielska, Agata A., Walid K. Chatila, Henry Walch, Nikolaus Schultz, Zsofia K. Stadler, Jinru Shia, Diane Reidy-Lagunes y Rona Yaeger. "Tumor Mutational Burden and Mismatch Repair Deficiency Discordance as a Mechanism of Immunotherapy Resistance". Journal of the National Comprehensive Cancer Network 19, n.º 2 (febrero de 2021): 130–33. http://dx.doi.org/10.6004/jnccn.2020.7680.
Texto completoTesis sobre el tema "Mesothelioma, immune-checkpoint inhibitors, tumor mutational burden"
Daffinà, Maria Grazia. "PREDICTIVE BIOMARKER OF LONG TERM SURVIVAL IN MESOTHELIOMA PATIENTS TREATED WITH IMMUNE CHECKPOINT INHIBITORS". Doctoral thesis, Università di Siena, 2021. http://hdl.handle.net/11365/1160848.
Texto completoCapítulos de libros sobre el tema "Mesothelioma, immune-checkpoint inhibitors, tumor mutational burden"
Emancipator, Kenneth, Jianda Yuan, Razvan Cristescu, Deepti Aurora-Garg y Priti S. Hegde. "Predictive Biomarkers (Programmed Death Ligand 1 Expression, Microsatellite Instability, and Tumor Mutational Burden) for Response to Immune Checkpoint Inhibitors". En Cancer Immunotherapy Principles and Practice. 2a ed. New York, NY: Springer Publishing Company, 2021. http://dx.doi.org/10.1891/9780826137432.0045.
Texto completoActas de conferencias sobre el tema "Mesothelioma, immune-checkpoint inhibitors, tumor mutational burden"
Sousa, Romualdo Barroso, Svitlana Tyekucheva, Pedro Exman, Renato Umeton, F. Stephen Hodi, Eric P. Winer, Nancy U. Lin y Sara M. Tolaney. "TUMOR MUTATIONAL BURDEN (TMB) IS A POTENTIAL PREDICTOR OF RESPONSE TO IMMUNE CHECKPOINT INHIBITORS (ICI) IN METASTATIC TRIPLE-NEGATIVE BREAST CANCER (MTNBC)". En Brazilian Breast Cancer Symposium. v29s1, 2019. http://dx.doi.org/10.29289/259453942019v29s1g04.
Texto completoHsieh, Yi-Lin, Pei-Ning Yu, Yi-Hua Jan, Meng-Shao Lai, Woei-Fuh Wang, De-Wei Zhuo, Shu-Jen Chen, Jen-Hao Cheng, Kien Thiam Tan y Yu-Li Su. "Abstract 3177: Panel-derived tumor mutational burden (TMB) is associated with the response to the immune checkpoint inhibitors (ICIs) in urothelial cancers". En Proceedings: AACR Annual Meeting 2020; April 27-28, 2020 and June 22-24, 2020; Philadelphia, PA. American Association for Cancer Research, 2020. http://dx.doi.org/10.1158/1538-7445.am2020-3177.
Texto completoHu, Jing, Bixun Li, Bing Zou, Senming Wang, Ye Qiu, Maolin Yan, Zhiming Zeng et al. "Abstract 620: Associations of genomic alteration, tumor mutational burden with PD-L1 expression and response to immune checkpoint inhibitors in Chinese lung patients". En Proceedings: AACR Annual Meeting 2018; April 14-18, 2018; Chicago, IL. American Association for Cancer Research, 2018. http://dx.doi.org/10.1158/1538-7445.am2018-620.
Texto completoBarroso-Sousa, R., S. Tyekucheva, S. Pernas-Simon, P. Exman, E. Jain, AC Garrido-Castro, M. Hughes et al. "Abstract P5-12-02:PTENalterations and tumor mutational burden (TMB) as potential predictors of resistance or response to immune checkpoint inhibitors (ICI) in metastatic triple-negative breast cancer (mTNBC)". En Abstracts: 2018 San Antonio Breast Cancer Symposium; December 4-8, 2018; San Antonio, Texas. American Association for Cancer Research, 2019. http://dx.doi.org/10.1158/1538-7445.sabcs18-p5-12-02.
Texto completo